COMP <GO>
EBS vs UNH // ENTERPRISE SCALE & MARKET CAP
Emergent BioSolutions Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: EBS 5
— UNH 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $7.22 (+1.83%) • MKT CAP: $370.2M
market-cap
$370.2M
LAST: $410.91 (+0.94%) • MKT CAP: $368.83B
market-cap
$368.83B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EBS VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EBS | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.10% | 88.57% | -32.47 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.90% | 11.47% | -2.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.6x | 16.4x | -9.85 | EBS | /valuation <GO> |
| Free Cash Flow Yield | — | 6.48% | — | TIE | /fcf-yield <GO> |
| Operating Margin | 13.50% | 4.82% | +8.68 | EBS | /operating-margins <GO> |
| Net Profit Margin | 7.10% | 3.14% | +3.96 | EBS | /net-margins <GO> |
| Revenue Growth (YoY) | -28.80% | 6.46% | -35.26 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.41 | 3.12 | -1.71 | UNH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | EBS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.74% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.0 | 59.2 | -6.22 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.5x | 17.1x | -10.59 | EBS | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $370.2M | $368.83B | -$368.46B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EBS REV | UNH REV | EBS GROSS % | UNH GROSS % | EBS FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $742.9M | $447.57B | 56.1% | 88.7% | $156.8M | $16.07B |
| FY 2024 | $1.04B | $400.28B | 34.7% | 88.3% | $35.8M | $20.70B |
| FY 2023 | $1.05B | $371.62B | — | 89.6% | -$206.3M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EBS // BETA —
UNH // BETA 0.33